vs
Side-by-side financial comparison of Travere Therapeutics, Inc. (TVTX) and Wheels Up Experience Inc. (UP). Click either name above to swap in a different company.
Wheels Up Experience Inc. is the larger business by last-quarter revenue ($183.8M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs -10.2%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs -3.4%).
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
Wheels Up is a provider of "on demand" private aviation in the United States and one of the largest private aviation companies in the world. It was founded in 2013 by Kenny Dichter, using a membership/on-demand business model. Wheels Up members can book private aircraft from the company fleet and third-party operators using a mobile application.
TVTX vs UP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $129.7M | $183.8M |
| Net Profit | — | $-28.9M |
| Gross Margin | 98.0% | 14.3% |
| Operating Margin | -25.0% | -0.9% |
| Net Margin | — | -15.7% |
| Revenue YoY | 73.4% | -10.2% |
| Net Profit YoY | — | 67.0% |
| EPS (diluted) | $0.04 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $129.7M | $183.8M | ||
| Q3 25 | $164.9M | $185.5M | ||
| Q2 25 | $114.4M | $189.6M | ||
| Q1 25 | $81.7M | $177.5M | ||
| Q4 24 | $74.8M | $204.8M | ||
| Q3 24 | $62.9M | $193.9M | ||
| Q2 24 | $54.1M | $196.3M | ||
| Q1 24 | $41.4M | $197.1M |
| Q4 25 | — | $-28.9M | ||
| Q3 25 | $25.7M | $-83.7M | ||
| Q2 25 | $-12.8M | $-82.3M | ||
| Q1 25 | $-41.2M | $-99.3M | ||
| Q4 24 | — | $-87.5M | ||
| Q3 24 | $-54.8M | $-57.7M | ||
| Q2 24 | $-70.4M | $-97.0M | ||
| Q1 24 | $-136.1M | $-97.4M |
| Q4 25 | 98.0% | 14.3% | ||
| Q3 25 | 99.0% | 6.8% | ||
| Q2 25 | 98.7% | 8.3% | ||
| Q1 25 | 94.3% | 10.8% | ||
| Q4 24 | 96.6% | 13.9% | ||
| Q3 24 | 97.4% | 13.9% | ||
| Q2 24 | 96.2% | 2.3% | ||
| Q1 24 | 96.4% | -0.6% |
| Q4 25 | -25.0% | -0.9% | ||
| Q3 25 | 15.1% | -33.1% | ||
| Q2 25 | -11.1% | -31.4% | ||
| Q1 25 | -52.2% | -45.5% | ||
| Q4 24 | -81.2% | -26.0% | ||
| Q3 24 | -89.3% | -21.6% | ||
| Q2 24 | -125.1% | -40.3% | ||
| Q1 24 | -336.5% | -42.9% |
| Q4 25 | — | -15.7% | ||
| Q3 25 | 15.6% | -45.1% | ||
| Q2 25 | -11.1% | -43.4% | ||
| Q1 25 | -50.4% | -55.9% | ||
| Q4 24 | — | -42.7% | ||
| Q3 24 | -87.1% | -29.8% | ||
| Q2 24 | -130.1% | -49.4% | ||
| Q1 24 | -328.9% | -49.4% |
| Q4 25 | $0.04 | $-0.04 | ||
| Q3 25 | $0.28 | $-0.12 | ||
| Q2 25 | $-0.14 | $-0.12 | ||
| Q1 25 | $-0.47 | $-0.14 | ||
| Q4 24 | $-0.71 | $-0.13 | ||
| Q3 24 | $-0.70 | $-0.08 | ||
| Q2 24 | $-0.91 | $-0.14 | ||
| Q1 24 | $-1.76 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.0M | $133.9M |
| Total DebtLower is stronger | — | $671.3M |
| Stockholders' EquityBook value | $114.8M | $-392.1M |
| Total Assets | $605.2M | $968.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.0M | $133.9M | ||
| Q3 25 | $110.9M | $125.3M | ||
| Q2 25 | $75.2M | $107.0M | ||
| Q1 25 | $61.9M | $171.8M | ||
| Q4 24 | $58.5M | $216.4M | ||
| Q3 24 | $36.4M | $115.9M | ||
| Q2 24 | $32.3M | $141.5M | ||
| Q1 24 | $43.3M | $180.9M |
| Q4 25 | — | $671.3M | ||
| Q3 25 | — | $766.5M | ||
| Q2 25 | — | $770.5M | ||
| Q1 25 | — | $765.8M | ||
| Q4 24 | — | $761.3M | ||
| Q3 24 | — | $596.9M | ||
| Q2 24 | — | $597.4M | ||
| Q1 24 | — | $603.2M |
| Q4 25 | $114.8M | $-392.1M | ||
| Q3 25 | $73.6M | $-374.5M | ||
| Q2 25 | $32.7M | $-347.8M | ||
| Q1 25 | $32.8M | $-288.1M | ||
| Q4 24 | $59.1M | $-202.1M | ||
| Q3 24 | $-30.5M | $-117.7M | ||
| Q2 24 | $15.1M | $-72.2M | ||
| Q1 24 | $74.1M | $936.0K |
| Q4 25 | $605.2M | $968.8M | ||
| Q3 25 | $538.6M | $973.0M | ||
| Q2 25 | $555.3M | $1.0B | ||
| Q1 25 | $548.8M | $1.1B | ||
| Q4 24 | $594.1M | $1.2B | ||
| Q3 24 | $504.4M | $1.0B | ||
| Q2 24 | $551.1M | $1.1B | ||
| Q1 24 | $663.5M | $1.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 644.43× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.7M | $-18.4M |
| Free Cash FlowOCF − Capex | — | $-58.3M |
| FCF MarginFCF / Revenue | — | -31.7% |
| Capex IntensityCapex / Revenue | — | 21.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-259.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.7M | $-18.4M | ||
| Q3 25 | $14.3M | $-37.1M | ||
| Q2 25 | $5.0M | $-62.9M | ||
| Q1 25 | $-42.2M | $-47.9M | ||
| Q4 24 | $-35.7M | $37.9M | ||
| Q3 24 | $-42.5M | $-16.9M | ||
| Q2 24 | $-40.2M | $-25.2M | ||
| Q1 24 | $-119.0M | $-73.8M |
| Q4 25 | — | $-58.3M | ||
| Q3 25 | $14.2M | $-60.4M | ||
| Q2 25 | — | $-78.6M | ||
| Q1 25 | — | $-62.6M | ||
| Q4 24 | — | $-70.2M | ||
| Q3 24 | — | $-21.9M | ||
| Q2 24 | $-40.3M | $-30.8M | ||
| Q1 24 | — | $-77.8M |
| Q4 25 | — | -31.7% | ||
| Q3 25 | 8.6% | -32.6% | ||
| Q2 25 | — | -41.5% | ||
| Q1 25 | — | -35.3% | ||
| Q4 24 | — | -34.3% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | -74.5% | -15.7% | ||
| Q1 24 | — | -39.5% |
| Q4 25 | — | 21.7% | ||
| Q3 25 | 0.1% | 12.5% | ||
| Q2 25 | — | 8.3% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 52.8% | ||
| Q3 24 | 0.0% | 2.6% | ||
| Q2 24 | 0.2% | 2.9% | ||
| Q1 24 | 0.0% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.56× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
UP
Segment breakdown not available.
